Drug Profile
HM 04
Alternative Names: HM-04Latest Information Update: 28 Aug 2023
Price :
$50
*
At a glance
- Originator Helsinn
- Class Obesity therapies; Small molecules
- Mechanism of Action Ghrelin receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Prader-Willi syndrome
Most Recent Events
- 28 Aug 2023 No recent reports of development identified for phase-I development in Prader-Willi-syndrome in Switzerland
- 10 Jan 2023 HM 04 is available for licensing as of 10 Jan 2023. https://helsinn.com/our-science/pipeline/#other (Helsinn pipeline, January 2023)
- 27 Jul 2020 Phase-I clinical trials in Prader-Willi syndrome in Switzerland (unspecified route) (Helsinn's pipeline, July 2020)